Articles On Invion (ASX:IVX)

Invion’s (IVX) Photosoft compound demonstrates more than 99 per cent inhibition against the Zika virus when exposed to specific light wavelengthsThe results come from in vitro studies that were carried out by leading contract research and c...

There’s a new development in the fight against the Zika virus. Invion (ASX:IVX) has just demonstrated that its Photosoft compounds were >99% effective in cell-based assays following the application of light. The study showed that Photoso...

Aussie markets are flat, flat, flat (actually the benchmark found 0.1%) Banks are lower, consumer names higher Explorers Devex and Tempus have found big things in the ground   There’s about 15 minutes of trade on the ASX and I’m calling b...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

The ASX 200 ends ever so slightly up, XEC finds 0.4% Gains in consumer discretionary, tech offset big losses for energy, resources, materials. South Korea, Kiwi’s lift rates ahead of tonight’s US CPI read Investors are facing crunch time...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

HitIQ and Volpara sign major deals in the US ECS Botanics makes first cannabis flower shipment to NZ Invex to commence Phase III study in Australia Following its extension contract with New Zealand Rugby a couple of weeks ago, HitIQ (ASX:...

The ASX is set to open more than 1% lower today as Wall Street plunges overnight Tech stocks led the selloff in the US Bitcoin is set to be regulated as a commodity by the US SEC The ASX is poised to open more than 1% lower this morning,...

Invion (IVX) confirms combination therapy of INV043 and immune checkpoint inhibitors (ICI) is more effective than just ICI therapy in its latest proof-of-concept (PoC) study The findings are from Invion’s third PoC study undertaken by its...

Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Life sciences company Invion (ASX: IVX) is raising $15 million to continue developing the Photosoft technology and expand its addressable markets for treating cancer and related diseases using the next generation technology. Invion has exec...

Invion (IVX) is aiming to raise $15 million in additional capital to help fund the expansion of its Photosoft technology co-development deal IVX and RMW Cho Group will co-develop the tumour regression treatment technology for use on cance...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

The ASX had a positive finish to the week although it is in negative territory for the week. The ASX 200 closed at 7,443 points which is up 0.83% from yesterday but slightly down from the 7,457 mark it closed at last Friday. Today, the only...

Invion (IVX) ends the week in a trading halt while it plans the details of an upcoming capital raising The company will remain in the halt until November 16 or when more details are released, whichever occurs first On October 28, Invion r...

Life sciences outfit Invion is seeking $15 million to expand its technology licences for cancer treatment.

After a few weeks when the Hot Money column briefly turned into a ‘bizarro Viagold update’, the ASX put an end to that when it put the obscure rare earths play into suspension on October 15, pending “further enquiries”. This week a new lead...

After a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than 1% today The ASX followed a plunge on Wall Street with the ASX 200 closing at 7,324, which was 1.44% lower than yesterday’s close. While Wal...

Local stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper drop of ~0.8% for the microcap Emerging Markets Index. The ASX opened with a weak lead from Wall Street, after a fortnight of steady gains...

The Invion Ltd (ASX: IVX) share price is on the move during late afternoon trade. This comes after the clinical-stage drug development company announced the pilot study results from its latest Proof-of-Concept (PoC) studies. At the time of...

A pilot proof-of-concept study by life sciences company Invion (ASX: IVX) has shown a complete regression of triple negative breast cancer (TNBC) in vivo following treatment with lead drug INV043. Conducted by Invion research partner Hudson...

Life sciences group Invion Group (ASX: IVX) has progressed the development of its next-generation photodynamic therapy for the treatment of various illnesses, boosted by part proceeds of a $4.5 million capital raising. In June, the company...

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

While Invion Group (ASX: IVX) progresses its next-generation photodynamic therapy INV043 for treating cancers, it is also advancing the therapy’s potential in combating bacterial, viral, fungal, parasitic diseases and atherosclerosis, which...

Life sciences company Invion Group (ASX: IVX) is rapidly advancing its next-generation photodynamic therapy INV043 for treating numerous cancers. The drug is under development in collaboration with the world-leading Hudson Institute of Medi...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

On the back of promising proof-of-concept results on a range of cancers, Invion Group (ASX: IVX) is looking to advance its novel photodynamic therapy (PDT) technology for the treatment of atherosclerosis and infectious diseases, and expand...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The armed forces could be called upon to enforce Sydney’s strict lockdown, and we might see troops on the streets as early as Monday. On the bourse, the benchmark ASX 200 has closed 0.40% lower on Friday, but was flat for the week. The mini...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

Small caps have dipped for a second straight day following their seven-day winning streak. The Small Ordinaries index closed yesterday down 12.1 points, or 0.37 per cent, to 3,278.8. Larger companies fared a little bit better, with the ASX2...

Investors will be watching for updates on Traka Resources (ASX:TKL) this week, after the gold explorer ripped higher on no news to post an RSI reading of 91. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Re...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...